Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics

Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics.  “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic.  We intend on dosing our first patients for A1AT deficiency by the end of this year…

Proteomic Studies of Age-Related Ocular Diseases

A Cleveland Clinic lab has found evidence to support the theory that age-related macular degeneration (AMD) is an inflammatory disease with varying ways to progress to advanced dry and wet AMD.  Focusing on proteomic studies to discover biomarkers and molecular mechanisms of AMD and glaucoma, John W. Crabb, PhD, and his colleagues found many proteins…